2022
DOI: 10.1111/jcpt.13809
|View full text |Cite
|
Sign up to set email alerts
|

Real‐world use of IBI305 , a bevacizumab biosimilar, in a tertiary caner‐specialized hospital in China

Abstract: What Is Known and Objective: To investigate and describe the real-world use of IBI305, a biosimilar of bevacizumab, across all approved indications in the first 12 months since its entry in National cancer center of China.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
references
References 17 publications
0
0
0
Order By: Relevance